ProKidney Corp.
NASDAQ:PROKBiotechnology
+$0.02 today
- Market cap
- $349.70M
- Beta
- 1.70
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.53
Volume 1.80M
Average 0.96M
PROK Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
ProKidney Corp.NASDAQ: PROK
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 4.2% from a year ago
Cash & equivalents stood at $101.9M at the end of Q1 FY2026, up 4.2% from a year earlier and down 6.1% from the prior quarter. Over 3 fiscal years it compounded at -39.5% a year.
Context
- Cash & equivalents amounted to 34.8% of total assets at the end of Q1 FY2026, up 10.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +4.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 108.54M USD
- Year-over-year change
- +9.5%
- 4-year CAGR
- +51.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 108.54M | +9.5% |
| FY2024 | 2024-12-31 | 99.12M | +63.4% |
| FY2023 | 2023-12-31 | 60.65M | -87.6% |
| FY2022 | 2022-12-31 | 490.25M | +2284.7% |
| FY2021 | 2021-12-31 | 20.56M | — |
Cash & Equivalents vs competitors
How PROK compares with its peers on the latest reported figures
- PROK's Mar 2026 cash & equivalents of $101.9M is the 3rd highest of the 7 companies compared; the peer median is $34.29M.
- Its year-over-year change of +4.2% is the 5th highest of 7, against a peer median of +49.7%.
- Cash & equivalents amounts to 34.8% of total assets for PROK, versus a peer median of 11.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $198.77M | -32.5% | +23.7% | 47.4% | |
| Sep 2026 | $123.54M | +11.4% | +14.7% | 14.6% | |
| Mar 2026 | $101.9M | +4.2% | -39.5% | 34.8% | |
| Mar 2026 | $37.37M | +89.0% | +300.4% | 58.0% | |
| Mar 2026 | $31.21M | +1.3% | -10.9% | 6.2% | |
| Mar 2026 | $4.87M | +88.0% | +49.0% | 9.2% | |
| Dec 2025 | $1.18M | +1102.0% | +17.9% | 5.7% | |
| Peer median (excluding PROK) | $34.29M | +49.7% | +20.8% | 11.9% | |
Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20.56M | 490.25M | 60.65M | 99.12M | 108.54M |
| Short-term Investments | 0 | 0 | 302.3M | 259.17M | 161.48M |
| Net Receivables | 0 | 0 | 1.38M | 2.45M | 1.13M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 25K | 1.38M | 9K | 19.45M | 2.8M |
| Total Current Assets | 27.27M | 504.72M | 374.15M | 395.88M | 280.68M |
| Property, Plant & Equipment (Net) | 12.6M | 13.06M | 46.41M | 45.19M | 54.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 428K | 213K | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 13.03M | 13.28M | 46.41M | 45.19M | 54.9M |
| Total Assets | 40.3M | 518M | 420.55M | 441.07M | 335.57M |
| Account Payables | 2.83M | 3.04M | 5.1M | 3.63M | 940K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 278K | 1.47M | 682K | 1.07M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.83M | 3.36M | 7.52M | 11.45M | 11.84M |
| Total Current Liabilities | 12.31M | 10.87M | 25.04M | 36.22M | 30.74M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 278K | 568K | 748K | 1.07M |
| Total Non-current Liabilities | 1.07M | 2.18M | 4.18M | 3.22M | 4.04M |
| Total Liabilities | 13.38M | 13.06M | 29.22M | 39.44M | 34.78M |
| Common Stock | 188.43M | 24K | 23K | 29K | 30K |
| Retained Earnings | (161.51M) | (1.1B) | (1.14B) | (1.2B) | (1.27B) |
| Accumulated OCI | 0 | 0 | 130K | 130K | 56K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 1.6B | 1.49B | 1.4B | 1.31B |
| Total Equity | 26.92M | 504.94M | 391.34M | 401.64M | 300.79M |
| Total Debt | 1.33M | 2.4M | 4.41M | 3.24M | 4.04M |
| Net Debt | (19.22M) | (487.85M) | (56.24M) | (95.88M) | (104.5M) |
ProKidney Corp.
NASDAQ:PROK
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.